INTRODUCTION
Our research group has been involved in the development of cholinesterases (ChEs) inhibitors as potential drugs of Alzheimer's disease (AD). 1 Tacrine (1) was the first approved ChEs inhibitor by the FDA for the treatment of AD, although its side effects, the search for tacrine hybrids is very important. The bis(7)-tacrine analogues linked by an alkylene chain (bis(n)-cognitin) were prepared and it was proved that these dimeric molecules of tacrine offered a much stronger potency. As part of our studies directed towards the synthesis and biological screening for compounds with ChEs inhibitory activity, we describe herein or studies on the synthesis of a new series of tacrine-lophine hybrids linked by an alkylene chain. Figure1. Tacrine, Lophine and tacrine-lophine hybrid.
RESULTS AND DISCUSSION
Tacrine-lophine hybrids linked by an alkylene chain were prepared as described in Scheme 1. Compounds 4 were synthesized using a previously reported method. 2 The one-pot four-component reaction of 4, aldehydes 5, benzils 6 and NH 4 OAc (7) was carried out in the presence of several Lewis to produce the respective hybrids 3a-g. InCl 3 was found as the best catalyst for these reactions. All reactions were performed in refluxing EtOH for 96h.
In Table 1 are presented some examples of tacrine-lophine hybrids linked by an alkylene chain. We also synthesized the hybrids bis(7)-lophine and bis(7)-tacrine in order to subject to the ChEs inhibitory activity studies. 
CONCLUSION
In summary, we have developed an important four-component one-pot condensation synthesis of tacrine-lophine hybrids. The AChE and BuChE biological screening of several new compounds are currently underway.
